Efficacy of Cardiac Myosin Inhibitors in Symptomatic Hypertrophic Cardiomyopathy: An Updated Meta-Analysis and Systematic Review
International Journal of Cardiovascular Sciences · 03.06.2026 · 39
DOI: 10.36660/ijcs.20250092 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift International Journal of Cardiovascular Sciences, erschienen am 03.06.2026. Verfasst von Pedro Henrique Tavares Fogaça und 5 weiteren Autor:innen. Die Arbeit nennt 33 Literaturangaben.
Abstract (Originalsprache)
Background
This study evaluates the efficacy of cardiac myosin inhibitors (CMI), which appear to be an innovative alternative for hypertrophic cardiomyopathy (HCM), a disease lacking highly effective pharmacologic treatments.
Objective
To provide updated efficacy data on CMI (aficamten or mavacamten) in symptomatic HCM. Materials and methods: We searched PubMed, Embase, and Cochrane databases for randomized controlled trials comparing CMI to placebo in symptomatic HCM, reporting: (1) New York Heart Association (NYHA) functional class improvement; (2) change from baseline in Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS); (3) percent change from baseline in left ventricular outflow tract (LVOT) gradient at rest and after Valsalva maneuver; and (4) serious adverse events. Heterogeneity was examined with I2 statistics, and p values < 0.05 indicated sta tistical significance. Continuous endpoints were analyzed using pooled mean difference (MD), and binary endpoints were analyzed using odds ratios (OR), both with 95% confidence intervals (CI).
Results
We included six RCTs with 826 patients, 443 of whom received CMI. Compared to placebo, NYHA class improvement was more frequent in patients receiving CMI (OR: 4.10; 95% CI: 2.79 to 6.02; p < 0.00001), with significant differences in KCCQ-CSS change (MD: 7.15; 95% CI: 4.21 to 10.10; p < 0.00001), as well as in LVOT gradient change at rest (MD: −38.25; 95% CI: −46.76 to −29.74; p < 0.00001) and after Valsalva maneuver (MD: −46.49; 95% CI: −54.70 to −38.27; p < 0.00001). There were no significant differences in serious adverse events (OR: 0.64; 95% CI: 0.31 to 1.31; p = 0.22).
Conclusion
CMI shows greater efficacy than placebo in treating symptomatic HCM.
Zitieren
APA
Fogaça, P. H. T., Alves, G. G., Fagundes, C. S. S., Scheinpflug, F. L., Fogaça, J. C. T., & Marques, M. D. (2026). Efficacy of Cardiac Myosin Inhibitors in Symptomatic Hypertrophic Cardiomyopathy: An Updated Meta-Analysis and Systematic Review. International Journal of Cardiovascular Sciences, 39. https://doi.org/10.36660/ijcs.20250092
Vancouver
Fogaça PHT, Alves GG, Fagundes CSS, Scheinpflug FL, Fogaça JCT, Marques MD. Efficacy of Cardiac Myosin Inhibitors in Symptomatic Hypertrophic Cardiomyopathy: An Updated Meta-Analysis and Systematic Review. International Journal of Cardiovascular Sciences. 2026;39. doi:10.36660/ijcs.20250092
BibTeX
@article{Fogaa2026,
author = {Fogaça, Pedro Henrique Tavares and Alves, Gabriel Grando and Fagundes, Camila Sales Sales and Scheinpflug, Fernanda Lavarda and Fogaça, João Candido Tavares and Marques, Mateus Diniz},
title = {Efficacy of Cardiac Myosin Inhibitors in Symptomatic Hypertrophic Cardiomyopathy: An Updated Meta-Analysis and Systematic Review},
journal = {International Journal of Cardiovascular Sciences},
year = {2026},
volume = {39},
doi = {10.36660/ijcs.20250092}
}
EUVIMED